More Mature Immune “Outposts” Appear in Lung Tumors After Pulsed Electric Field Ablation; Efficacy Still Awaits Clinical Proof

Cancer ablation typically focuses on destroying localized tumors, but an early human study raises another possibility: the effects of brief electrical pulses may extend beyond cell death and make immune responses within tumors more organized. Researchers observed more mature tertiary lymphoid structures with germinal centers in early-stage non-small cell lung cancers treated with Aliya pulsed electric field ablation.

The INCITE ES trial enrolled 47 patients across four centers in Spain, the Netherlands, and Hong Kong. Patients underwent diagnostic biopsy before surgical tumor resection; the treatment group received pulsed electric field ablation after biopsy, while the control group underwent biopsy alone. The study used an open-label, nonrandomized design, and patients who did not receive ablation could choose to join the control group, meaning the two groups may not have been fully comparable at baseline.

Post-resection tissue examination showed that 47% of tumors in the treatment group contained tertiary lymphoid structures with germinal centers, compared with 24% in the control group. These structures resemble temporary immune outposts established within tumors, where immune cells such as B cells and T cells can gather. Their germinal centers are important sites for B-cell maturation, selection, and the formation of immune memory. In multiple cancers, they have been associated with better prognosis or response to immune checkpoint inhibitors, but association alone does not establish a treatment effect.

Other analyses also pointed to a more active immune environment. After ablation, tumor tissue showed increased CXCL13 signaling, which recruits and organizes lymphocytes, as well as increases in germinal center-related populations such as class-switched memory B cells and plasma cells. Blood tests found increases in HMGB1 and circulating cytotoxic T cells. Together, these results suggest that both local and systemic immunity were affected, but they do not yet show that immune cells can eliminate residual cancer cells, reduce recurrence, or prolong survival.

The Aliya system uses microsecond-scale electrical pulses to destroy tumor tissue, unlike ablation methods that rely on high-temperature cauterization. The research team believes that preserving part of the tumor’s stromal architecture may provide conditions for immune-cell aggregation and the formation of tertiary lymphoid structures. If this mechanism is supported by subsequent research, pulsed electric field ablation may have the potential to serve as an adjunct to immunotherapy rather than merely as a local treatment tool.

The current evidence remains exploratory. The trial’s registered primary endpoint was serious device- or procedure-related adverse events within 30 days after surgery; immune activation and patient benefit were not prespecified primary endpoints. In addition, the sample was limited, the comparison was not randomized, and the tissue and blood analyses may not have included all participants, so selection bias and chance differences cannot be ruled out.

The trial was sponsored by Galvanize Therapeutics, and the paper’s authors included company personnel. Participating researcher Tullia C. Bruno also disclosed serving as a scientific advisor to the company and providing consulting services. Larger randomized studies tracking recurrence, survival, and response to immunotherapy are needed to determine whether these more orderly immune signals truly translate into benefits that patients can experience.